PROTEOMTECH, INC.

Basic Information

PROTEOMTECH, INC.
5980 HORTON ST, STE 405
EMERYVILLE, CA, 94608

Company Profile

n/a

Additional Details

Field Value
DUNS: 110482911
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. p53 Fusion Protein as an Oncology Therapeutic

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The aim of this proposal is to test the feasibility of the use of a p53 fusion protein as a cancer therapeutic. World wide 10 million people are diagnosed every ye ...

    SBIR Phase I 2007 Department of Health and Human Services
  2. Recombinant Des-Kringle Derivatives of Plasmin for Treatment of Peripheral Arteri

    Amount: $100,000.00

    Thrombolytic treatment with plasminogen activators (PA) such as tissue plasminogen activator (tPA) has been used not only for treatment of acute myocardial infarction, but also peripheral arterial occ ...

    SBIR Phase I 2006 Department of Health and Human Services
  3. Recombinant h-VEGI as an Anit-Angiogenesis Therapeutic

    Amount: $750,197.00

    DESCRIPTION (provided by applicant): Blocking or inhibiting tumor blood vessel growth (angiogenesis) remains a critical focal point for anticancer drug development. Studies on Vascular Endothelial ...

    SBIR Phase II 2004 Department of Health and Human Services
  4. Bioengineering Prourokinase for Improved Fibrinolysis

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The objective of this proposal is to bioengineer a mutant variant of prourokinase (proUK) with improved therapeutic properties for treatment of acute myocardial in ...

    SBIR Phase I 2004 Department of Health and Human Services
  5. Recombinant HBxAg Production For Anti-cancer Therapeutic

    Amount: $100,000.00

    DESCRIPTION (provided by investigator): Chronic infection with hepatitis B virus (HBV) is associated with a high incidence of liver diseases, including hepatocellular carcinoma (HCC). Hepatitis B viru ...

    SBIR Phase I 2004 Department of Health and Human Services
  6. Recombinant h-VEGI as an Anticancer Therapeutic

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Blocking or inhibiting blood vessel growth (angiogenesis) remains a critical focal point for anticancer drug development. Studies on Vascular Endothelial Growth In ...

    SBIR Phase I 2003 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government